From $1.6 Billion to $133.5 Billion

Data scope and clarifications

The long-run scale shift

Source: USITC DataWeb, 1991–2025 annual series aggregated from HTS 4-digit data. 1989–1990 values from US Census Bureau trade in goods with Ireland (USITC annual series begins 1991).

Five identifiable waves define the long-run trajectory:

• 1990s: Steady expansion from a $2 billion base as pharmaceutical and chemical manufacturing scales up in Ireland following the 1980s IDA investment drive. By 1999 imports reached $11.0 billion. Computing equipment (HTS 8471) and chemicals dominated the early mix.
• Early 2000s: Acceleration with pharma scaling – imports more than doubled between 2000 ($16.4B) and 2003 ($25.8B) as pharmaceutical manufacturing became the dominant export sector. Chemical intermediates (HTS 2933/2934) were the lead categories.
• 2005–2014: Plateau and reshape – total imports held in a $28–34 billion range but the underlying mix shifted. Finished dose production (HTS 3004) and medical devices grew while chemical intermediates flattened.
• 2015–2020: Biologics step-up – imports climbed from $39.4B in 2015 to $66.1B in 2020 as biologics manufacturing (HTS 3002) scaled. COVID-era pharmaceutical demand extended the trend.
• 2021–2025: GLP-1 surge – from $73.9B in 2021 to $133.5B in 2025, with the 2024 and 2025 jumps ($30 billion annually) driven almost entirely by HTS 2937 hormones (GLP-1 analogues).

The structural shift into pharmaceuticals

The most analytically significant feature of the 36-year data is not the total growth but the progressive concentration of that growth into a narrow set of pharmaceutical and chemical product categories. Using HTS chapters 29 (organic chemicals) and 30 (pharmaceutical products) as a proxy for pharma-related goods, the picture is unambiguous.

Source: USITC DataWeb, annual series. Pharma share = HTS chapters 29 (organic chemicals) + 30 (pharmaceutical products), divided by total Ireland-origin imports.

The major long-run headings

Within the pharmaceutical category, the product mix has itself evolved through successive generations. The dominant 4-digit HTS headings across the full period include:

• 2933 / 2934 / 2935 – Advanced chemical intermediates (nitrogen-containing heterocyclic compounds, nucleic acids, sulphonamides)
• 2937 – Hormones and derivatives (including GLP-1 analogues and prostaglandins)
• 3002 – Immunological products / biologics (vaccines, antisera, monoclonal antibodies)
• 3004 – Finished medicaments (packaged for retail or therapeutic use)
• 9021 / 9018 – Medical devices, implants and surgical instruments
• 9801 – US goods returned

Within those headings, the timeline of dominance evolved as follows:

• 1990s: Chemical intermediates – HTS 29 organic chemicals dominate early pharmaceutical exports, reflecting API and active ingredient manufacturing before the shift to finished dose production.
• 2000s: API-heavy growth – large-molecule active pharmaceutical ingredients and finished dose forms both grow rapidly as the major multinational pharmaceutical operations reach full scale.
• 2010s: Finished pharmaceuticals consolidate – HTS 3004 (finished medicaments) becomes the dominant category, reflecting the shift toward end-to-end manufacturing of packaged pharmaceutical products.
• Post-2015: Biologics scale – HTS 3002 (immunological products and biologics) becomes a major growth driver as Ireland becomes a global biologics manufacturing hub.
• 2024–2025: GLP-1 surge – HTS 2937 (hormones and related compounds, including GLP-1 analogues) overtakes all other categories in value, driven by the growth of GLP-1 diabetes and weight-loss drugs manufactured in Ireland.

Source: USITC DataWeb. The HTS 2937 trajectory is especially striking: Below $0.02B until 2019, $3.14B in 2020, $15.42B in 2024, $56.30B in 2025.

The 2025 monthly pattern: Tariff timing reshapes the cadence

The long-run picture shows a structural trend. The 2025 monthly pattern shows something different – that when the annual total is this large and this concentrated, the timing of shipments responds sharply to US trade policy expectations. The 2024 monthly pattern is relatively smooth; the 2025 pattern is driven by tariff deadlines.

Source: USITC DataWeb, monthly general customs value. 2025 exact values (USD billions): Jan $13.64, Feb $15.27, Mar $30.73, Apr $10.87, May $13.41, Jun $6.66, Jul $4.30, Aug $5.18, Sep $19.94, Oct $4.97, Nov $4.75, Dec $3.83.

Three features of the 2025 monthly data reshape how to read the $133.5 billion annual total:

• Spring pre-positioning: January-February-March 2025 together totalled $59.6 billion – 45% of the full year in the first quarter alone. March 2025 alone was $30.7 billion, more than double any previous month ever recorded and larger than total Ireland-US goods trade in any year before 2009. This pattern reflects US importers pulling forward inventory ahead of anticipated Section 232 pharmaceutical tariff action.
• Summer collapse: June through August totalled $16.1 billion combined – less than any single spring month. HTS 2937 recorded zero imports in July and August 2025. A category running at $56 billion per year does not stop producing for months; importers were drawing on spring-stockpiled inventory.
• September pulse: After the 21 August 2025 EU-US joint statement capping pharmaceutical tariffs at 15%, September rebounded to $19.9 billion as importers shipped under the clarified regime. October-November-December then fell back sharply, with HTS 2937 again recording zero monthly imports.

This matters for interpretation. The 2025 annual total of $133.5 billion is real in the sense that the goods crossed the US customs border. But 45% of the year in one quarter, with a second pulse driven by a specific policy date, means the annual figure reflects pulled-forward volume as well as underlying production growth. Any assessment of the “run-rate” of Ireland-US pharmaceutical trade needs to look at the full 12 months together and expect that future tariff deadlines will produce similarly front-loaded patterns.

What the long-run picture means now

The 36-year context reframes the current policy debates in three ways:

• The 2024–2025 surge is the latest phase of a 25-year structural transformation. Policy assessments that treat recent growth as a cyclical peak risk underestimating the structural depth of Ireland’s pharmaceutical manufacturing base. The concentration has been built up since the mid-1990s and reflects deliberate industrial policy successes.
• Concentration risk has compounded over decades. The progressive rise in pharmaceutical share from ~25% in 1991 to 81% in 2025 means that diversification away from pharmaceutical dependence – if that were a policy objective – would require extraordinary scale of new investment in other sectors, not marginal rebalancing.
• The exposure to US policy is structural. The 2025 monthly cadence shows that US trade policy decisions move Irish goods trade figures by tens of billions of dollars in a single quarter. The Section 232 pharmaceutical tariff outcome of April 2026 stabilised the immediate framework at 15% (with exemptions for companies in MFN agreements), but the pattern of monthly volatility is likely to persist wherever tariff deadlines recur.

The goods trade data alone does not define Ireland’s economy – it is far broader, encompassing services, technology, finance and indigenous enterprise. But within the specific channel of physical product exports to the United States, Ireland’s manufacturing platform is now a pharmaceutical manufacturing platform above all else, and the platform is sensitive to the timing of US trade policy actions as well as to their level.

Data source